LuX-Valve procedure for severe leaking tricuspid valve
Part of Heart & circulation clinical trials.
This trial tests a minimally invasive procedure (LuX-Valve placed through a neck vein) to treat severe leaking of the tricuspid valve. It may help people who are too high-risk for open-heart tricuspid surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be age 50 or older when you sign consent
- Have severe (or worse) tricuspid valve leaking confirmed by an echocardiogram
- Be in NYHA heart failure class III or IV (symptoms with limited activity or at rest)
- Have good left-heart pumping (left ejection fraction 50% or higher)
- Be considered high-risk for tricuspid surgery (heart team judgment, euroSCORE II 7 or higher)
- Not have certain heart or medical problems, like high lung pressure, prior tricuspid valve replacement, or active infection
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new device, called the Laplace TTVR System, to replace the tricuspid valve in people whose leaky valve (tricuspid regurgitation) continues to cause symptoms despite medical treatment. It may help if you have severe symptoms and are not a candidate for open-heart surgery.
This trial tests a new, less invasive valve device (TricValve) for people with severe tricuspid regurgitation who are not good candidates for open-heart surgery. It aims to see if this device can help your heart pump better and improve your symptoms.
This trial tests a new device that replaces a leaky tricuspid valve (a heart valve) without open-heart surgery. If your tricuspid valve isn't working well and medicines haven't helped enough, this procedure might improve your heart function and symptoms.
This study tests a new device to fix a leaky tricuspid valve without open-heart surgery. It is for people with severe leakage who are considered too high-risk for traditional surgery.
This trial tests whether a new minimally invasive valve replacement device (put through a catheter) can improve health in people with severe right-sided tricuspid valve leaking. It’s for patients who are considered too high-risk for standard open-heart tricuspid surgery.
This study tests a new, catheter-based procedure to treat moderate-to-severe leaking of the tricuspid valve (a heart valve on the right side). It’s for people who are high surgical risk and might benefit from replacing the valve without open-heart surgery.
Hear when a new Tricuspid Valve Regurgitation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.